Women's imaging firm Hologic is planning to acquire Focal Therapeutics, the developer of an implantable 3D marker to mark tumor excision sites during lumpectomy procedures.
Hologic plans to pay $125 million for the privately held company, which it will add to its Breast Health product portfolio. Focal Therapeutics generated about $16 million in revenue over the past 12 months.
Focal Therapeutics makes BioZorb, a 3D marker placed by surgeons to mark excision sites for monitoring and future treatments. BioZorb has an open design that allows for tissue in-growth during the healing process, according to Hologic.
